Publication: American Journal of Managed Care
Understanding that patients who are HER2-low are different from patients who are HER2-positive and -negative means having the right way to evaluate and identify these patients, explained Debra Patt, M.D., Ph.D., MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives at Texas Oncology.
Read the full article here.